title: In silico drug repositioning: what we need to know.
abstract: Drug repositioning, exemplified by sildenafil and thalidomide, is a promising way to explore alternative indications for existing drugs. Recent research has shown that bioinformatics-based approaches have the potential to offer systematic insights into the complex relationships among drugs, targets and diseases necessary for successful repositioning. In this article, we propose the key bioinformatics steps essential for discovering valuable repositioning methods. The proposed steps (repurposing with a purpose, repurposing with a strategy and repurposing with confidence) are aimed at providing a repurposing pipeline, with particular focus on the proposed Drugs of New Indications (DNI) database, which can be used alongside currently available resources to improve in silico drug repositioning.
authors.affiliation: ICF International at FDA National Center for Toxicological Research, Jefferson, AR 72079, USA.
authors.forename: Zhichao
authors.initials: Z
authors.lastname: Liu
authors.forename: Hong
authors.initials: H
authors.lastname: Fang
authors.forename: Kelly
authors.initials: K
authors.lastname: Reagan
authors.forename: Xiaowei
authors.initials: X
authors.lastname: Xu
authors.forename: Donna L
authors.initials: DL
authors.lastname: Mendrick
authors.forename: William
authors.initials: W
authors.lastname: Slikker
authors.forename: Weida
authors.initials: W
authors.lastname: Tong
mesh_terms: D019295:Computational Biology; D003198:Computer Simulation; D055808:Drug Discovery; D058492:Drug Repositioning